Gilead Sciences | GILD - Loan Capital


Gilead Sciences reported $20.86B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.48B 1.2B Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Incyte USD 29.41M 785K Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Merck USD 46.67B 77M Mar/2026
Moderna USD 603M 7M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025